A Study of Nystatin in the Prevention of Fungal Infections of the Mouth in Patients With AIDS or AIDS-Related Syndromes

Inclusion Criteria Concurrent Medication: Allowed: Experimental drugs (IND drugs) which are targeted specifically against the AIDS virus or which stimulate the immune system. Systemic or oral antibiotics. Patients must have AIDS or AIDS-related syndromes (HIV infection: Group III or IV, CDC classification) and not have been treated for oral candidiasis during the past year. Patients can be entered into the study who have: Other oral lesions due to Kaposi's sarcoma, herpes zoster, and herpes simplex. A positive or negative oral culture for Candida. Must be able to follow instructions regarding the use of a pastille. Exclusion Criteria Co-existing Condition: Patients with the following are excluded: Oral lesions diagnostic of oral candidiasis or systemic candidiasis. Suspected or proven candidal esophagitis. Patients with the following are excluded: Oral lesions diagnostic of oral candidiasis or systemic candidiasis. Receiving any effective antifungal agent orally or intravenously within 72 hours of study entry. Not expected to survive for at least 6 months. Unable to voluntarily maintain a pastille in the buccal cavity for approximately 20 minutes twice a day. Known hypersensitivity to nystatin. Suspected or proven candidal esophagitis. Prior Medication: Excluded within 72 hours of study entry: Any oral or intravenous antifungal agent.